This company has been marked as potentially delisted and may not be actively trading. Correvio Pharma (CORV) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock CORV Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Corvus Pharmaceuticals announces preclinical dataon soquelitinibNovember 14, 2024 | markets.businessinsider.comCorvus Pharmaceuticals options imply 17.7% move in share price post-earningsNovember 12, 2024 | markets.businessinsider.comAn Overview of Corvus Pharma's EarningsNovember 12, 2024 | benzinga.comAtea Pharmaceuticals Advances in HCV Treatment DevelopmentNovember 8, 2024 | markets.businessinsider.comCorbus Pharmaceuticals price target lowered to $75 from $80 at H.C. WainwrightNovember 8, 2024 | markets.businessinsider.comBuy Rating for Corbus Pharmaceuticals on Promising CRB-913 Obesity Treatment and Favorable Risk/Reward ScenarioNovember 6, 2024 | markets.businessinsider.comOzempic, Wegovy creator Novo Nordisk started with a love story, owned by philanthropic foundationNovember 3, 2024 | msn.comCoriolis Pharma Launches New U.S. Entity and Platform ServicesOctober 22, 2024 | markets.businessinsider.comIs Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts?October 3, 2024 | msn.comSpotlight on Corbus Pharmaceuticals: Analyzing the Surge in Options ActivitySeptember 23, 2024 | benzinga.comCorbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial DisappointsSeptember 20, 2024 | benzinga.comBuy Rating Affirmed for Corbus Pharmaceuticals Amid Promising Outlook for Novel Oral Weight Loss Therapy CRBP-913September 13, 2024 | markets.businessinsider.comMaxim Group Reaffirms Their Hold Rating on Reviva Pharmaceuticals Holdings (RVPH)September 6, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Holdings, Inc. (CRBP): This Small-Cap Healthcare Stock Is A Good Buy Right NowSeptember 4, 2024 | msn.comOptimistic Outlook on Corbus Pharmaceuticals’ Oncology and Obesity Drug Candidates Supports Buy RatingAugust 28, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimer's Top Stock Picks For the Next 12 MonthsAugust 27, 2024 | msn.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Corvus Pharmaceuticals (CRVS), Vir Biotechnology (VIR) and Cooper Co (COO)August 20, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitorsAugust 16, 2024 | marketwatch.comAnalysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Replimune Group (REPL) and Hookipa Pharma (HOOK)August 13, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms marketAugust 13, 2024 | marketwatch.comRaleigh pharma updates strategy for highly-anticipated COPD drugAugust 12, 2024 | bizjournals.comCollegium Pharmaceutical: Diversifying And GrowingAugust 9, 2024 | seekingalpha.comBuy Rating Affirmed for Reviva Pharmaceuticals Amid Patent Grants and Positive Clinical OutlookAugust 7, 2024 | markets.businessinsider.comCorbus Pharmaceuticals GAAP EPS of -$0.90August 6, 2024 | msn.comBuy Rating for Corbus Pharmaceuticals’ CRB-701 Based on Promising Oncology Trial Results and Therapeutic PotentialAugust 6, 2024 | markets.businessinsider.comLigand Pharmaceuticals Says President, Operating Chief Korenberg to ExitAugust 2, 2024 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the dayAugust 1, 2024 | marketwatch.comCorbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms marketJuly 22, 2024 | marketwatch.comAnalysts Offer Insights on Healthcare Companies: Cooper Co (COO), Vertex Pharmaceuticals (VRTX) and Guardant Health (GH)May 27, 2024 | markets.businessinsider.comTraws Pharma Showcases Promising COVID-19 Drug at ICAR ConferenceMay 23, 2024 | msn.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)May 16, 2024 | markets.businessinsider.comBig Pharma Split Corp Class AMay 15, 2024 | morningstar.comMCorbus Pharmaceuticals a new outperform at RBC on cancer, obesity assetsMay 13, 2024 | msn.comPositive Outlook for Verona Pharma with Strong Financial Position and Anticipated Drug ApprovalMay 13, 2024 | markets.businessinsider.comCardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart FailureMay 11, 2024 | businesswire.comAnalysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)May 10, 2024 | markets.businessinsider.comTraws Pharma Advances COVID-19 Treatment into First Human TrialsMay 9, 2024 | msn.comRaleigh pharma secures $650M to be ready for growth surgeMay 9, 2024 | bizjournals.comNutra Pharma Corp. (NPHC)May 7, 2024 | finance.yahoo.comCorbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | markets.businessinsider.comProtect Pharmaceutical Corp.April 19, 2024 | wsj.comStella Pharma Corp Ordinary Shares 4888April 16, 2024 | morningstar.comMNatco Pharma gets USFDA warning letter for Kothur plantApril 9, 2024 | msn.comHold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing ConcernsMarch 29, 2024 | markets.businessinsider.comCorvus: Q4 Earnings SnapshotMarch 19, 2024 | washingtonpost.com'This is a sleeping giant:' UC seals licensing deal with TRPV Pharmaceuticals for new heart failure drugMarch 15, 2024 | bizjournals.comCorbus Pharmaceuticals Stock Climbs on Narrower-Than-Expected 4Q LossMarch 13, 2024 | marketwatch.comGarware Fulflex India acquires Avcor Health Care Products to strengthen its medical product portfolioMarch 1, 2024 | msn.comChong Kun Dang Pharmaceutical Corp.February 17, 2024 | wsj.comSilver Creek Pharmaceuticals Appoints Mark Corrigan, M.D. As PresidentFebruary 12, 2024 | finance.yahoo.com Get Correvio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CORV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CORV Media Mentions By Week CORV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CORV News Sentiment▼0.000.94▲Average Medical News Sentiment CORV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CORV Articles This Week▼01▲CORV Articles Average Week Get the Latest News and Ratings for CORV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Correvio Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies VIRI News ELYM News OSTX News ATNM News AADI News EGRX News PYRGF News NNVC News IBIO News NBY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CORV) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Correvio Pharma Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Correvio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
